Výsledky vyhledávání

Akademický článek

Predictors of continuation for asenapine from real-world data in patients with schizophrenia

Autor: Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Daisuke Matsui, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Toshiyuki Shimizu, Yuji Murase, Yutaro Shimamoto, Yosuke Koshikawa, Masaki Kato

Publikováno v: Annals of General Psychiatry, Vol 23, Iss 1, Pp 1-8 (2024)

Abstract Background The continuation rates of pharmacotherapy in schizophrenia exhibit variability, a phenomenon influenced by the specific antipsychotic agent prescribed and patient-related factors such as age and duration of illness. In this contex

Externí odkaz: https://doaj.org/article/cad900ff761a4f22bb3f1212d86fa5c0

Zobrazit plný text záznamu

Akademický článek

Efficacy of HP-3070, A Once-Daily Asenapine Transdermal System, in the Treatment of Adults with Schizophrenia: A PANSS Five-Factor Analysis

Autor: Citrome L, Castelli M, Hasebe M, Terahara T, Faden J, Komaroff M

Publikováno v: Neuropsychiatric Disease and Treatment, Vol Volume 20, Pp 755-764 (2024)

Leslie Citrome,1 Mariacristina Castelli,2 Masami Hasebe,3 Takaaki Terahara,3 Justin Faden,4 Marina Komaroff2 1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 2Product Development, Noven Pharmaceuticals,

Externí odkaz: https://doaj.org/article/18e35effb1b3429b9d101777d39862ac

Zobrazit plný text záznamu

Akademický článek

Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study

Autor: Tomohiko Kimura, Akifumi Kanai, Hiroyuki Muraoka, Yuichiro Takahashi, Masatomo Ara, Ken Inada

Publikováno v: Neuropsychopharmacology Reports, Vol 44, Iss 1, Pp 158-164 (2024)

Abstract Aim Patients with cancer often experience nausea and vomiting (N/V), but may have difficulty using olanzapine (OLZ), a common antiemetic. Asenapine (ASE) is a multi‐acting receptor‐targeted antipsychotic like OLZ, although there is littl

Externí odkaz: https://doaj.org/article/1c7d83aac6b94f4f81e2e86230e4c050

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real‐world data

Autor: Yoshiteru Takekita, Shuichi Hiraoka, Yasuhiro Iwama, Daisuke Matsui, Nobuatsu Aoki, Haruhiko Ogata, Toshiya Funatsuki, Toshiyuki Shimizu, Yuji Murase, Yosuke Koshikawa, Masaki Kato, Toshihiko Kinoshita

Publikováno v: Neuropsychopharmacology Reports, Vol 44, Iss 1, Pp 234-239 (2024)

Abstract Aims A meta‐analysis of short‐term studies revealed no significant differences between the doses of asenapine, 10 and 20 mg/day, in the acute treatment of schizophrenia. However, it should be noted that many patients from clinical practi

Externí odkaz: https://doaj.org/article/efa7834839754f0899b8de123b473e06

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Effect of single-administration of d-sorbitol pretreatment on the bitterness and continued willingness to take asenapine: a randomized, single-blind, placebo-controlled, crossover trial

Autor: Shuhei Wada, Kunihiro Iwamoto, Hiroki Okumura, Hirotake Hida, Shuichi Hiraoka, Aya Kamei, Daisuke Mori, Kiyofumi Yamada, Masahiko Ando, Norio Ozaki, Masashi Ikeda

Publikováno v: BMC Psychiatry, Vol 24, Iss 1, Pp 1-9 (2024)

Abstract Background Asenapine has unique orally-related side effects, such as a bitter taste induced by sublingual administration, which often results in discontinuation of the medication. While the FDA has approved black-cherry-flavored asenapine, s

Externí odkaz: https://doaj.org/article/997bb93891c542c5a0bdd0b4dd1c5044

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Long‐term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow‐up for 52 weeks (P06125)—Secondary publication

Autor: Toshihiko Kinoshita, Yoshiteru Takekita, Shuichi Hiraoka, Fumihiro Tamura, Yasuhiro Iwama

Publikováno v: Neuropsychopharmacology Reports, Vol 43, Iss 3, Pp 328-337 (2023)

Abstract After completion of a 6‐week double‐blind trial of asenapine sublingual tablets (10 or 20 mg/day) versus placebo in Asian patients with acute exacerbation of schizophrenia, including Japanese patients, this open‐label study evaluated t

Externí odkaz: https://doaj.org/article/c9f1925f4a1344df9c5719adbca705e8

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial

Autor: Shuhei Wada, Kunihiro Iwamoto, Hiroki Okumura, Hirotake Hida, Shuichi Hiraoka, Aya Kamei, Daisuke Mori, Kiyofumi Yamada, Norio Ozaki

Publikováno v: BMC Psychiatry, Vol 23, Iss 1, Pp 1-6 (2023)

Abstract Background Antipsychotics are essential in the acute treatment of and maintenance therapy for schizophrenia, but medication adherence and long-term treatment continuity are needed to maximize their effectiveness. Each antipsychotic has vario

Externí odkaz: https://doaj.org/article/fbd0cfbc529443bca856c6ec29966647

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání